29″ December “2022” .Reuters.com/
Pfizer’s hemophilia B daaweynta hidda-wadaha waxay ku guulaysataa daraasadda marxaladda dambe
Pfizer Inc (PFE.N) oo ah shirkad Maraykan ah ayaa sheegtay Khamiista in daawaynta hidda-sidaha tijaabada ah ee daaweynta dhiig-yarida B, oo ah cillad naadir ah oo la iska dhaxlo, ay la kulantay hadafkeedii ugu weynaa ee daraasadda marxaladda dambe.
Xogta laga helay daraasadda ayaa muujisay in hal dose oo daawadu ay ka sarreeyeen heerka daryeelka hadda jira ee caawinaya dhimista heerka dhiigbaxa bukaannada qaba qaababka dhexdhexaadka ah iyo kuwa daran ee hemophilia B.
Cilad-xumada waxay caqabad ku noqotaa awoodda jidhku u leeyahay samaynta borotiinka xinjirowga dhiigga ee loo yaqaan factor IX.
Daaweynta Pfizer, fidnacogene elaparvovec, waxaa loogu talagalay in lagu caawiyo bukaanada inay soo saaraan factor IX naftooda ka dib daawaynta hal mar ah, oo ka soo horjeeda daawaynta hadda, kuwaas oo diiradda saaraya faleebo joogto ah borotiinka.
Daroogadu waxay shati ka siisay daawaynta hiddasidaha hemophilia B ee qaybta Roche’s (ROG.S) Spark Therapeutics unit sanadkii 2014 oo ay bixisay $20-milyan oo hore.
Pfizer waxa ay qorshaynaysaa in ay kala hadasho xogta marxalada dambe maamulada sharciyaynta ee Yurub iyo Maraykanka oo ay la wadaagto xog dheeraad ah oo ku saabsan daawaynta tijaabada shirka sayniska horaanta 2023.
Sida laga soo xigtay xogta dawladda, qiyaasta baahsanaanta xanuunka dhiigbaxa ee Maraykanka waa 12 xaaladood 100,000 ee lab ah ee hemophilia A iyo 3.7 xaaladood 100,000 ee lab ah ee hemophilia B. Bishii Nofembar, maamulaha caafimaadka Mareykanka ayaa ansixiyay daawaynta hidda-wadaha ee ugu horreeya, CSL Ltd iyo uniQure’s Hemgenix, si loo daweeyo hemophilia B.
Pfizer waxa kale oo ay tijaabinaysaa daawaynta hidda-sidaha kale ee tijaabada ah ee tijaabooyinka dambe sida daawaynta suurtagalka ah ee xanuunka dhiigbaxa hemophilia A iyo xanuunka murqaha ee Duchenne muscular dystrophy.